Skip to content
Signal Bureau What’s happening · what the record shows

Pfizer

One of the world's largest pharmaceutical companies — vaccines, oncology, and the drug pipeline behind them.

Coverage of Pfizer is holding steady : 6 signals on the latest tracked day, up 100% from its three-week baseline of 3, across 2 domains (down from 3 a week ago). That makes it the #113 most-covered of the 274 concerns we track.

What’s changed

What the reporting says

Across 51 tracked stories from 19 outlets, reporting on Pfizer most often describes regulatory approvals (8), launches or releases (6), funding rounds (1), IPOs or listings (1), legal rulings (1), acquisition (1).

It shows up alongside Bristol Myers Squibb (16), Astrazeneca (15), Novartis (13), FDA (14), Merck (14), Eli Lilly (13).

Two steps out: AI (through FDA, 14 shared stories on the weaker link); China (through FDA, 14 shared stories on the weaker link); CMS (through FDA, 14 shared stories on the weaker link); Colorectal Cancer (through FDA, 14 shared stories on the weaker link).

Tracked since Jun 25, with coverage on 19 separate days — concentrated in Biotech Pharma and Pharma Pipeline.

What the crowd is pricing

Coverage momentum and market odds are separate readings — one can move without the other. A price is what the crowd believes, shown as a signal, not a forecast of ours.
Ask the engine about Pfizer + Track Pfizer for a daily read
Counts computed from our committed signal record (Jul 15 – Aug 6, 6 tracked days). Informational only — not financial, legal, or investment advice. Prediction-market prices are shown as a signal of what the crowd believes. Terms · Privacy · page rendered Aug 8, 8:49 PM PT